All News

A caregiver discusses the challenges of always waiting to hear "the cancer is back."

The FDA has lifted a partial clinical hold on a phase 2 trial evaluating a novel therapy in patients with acute myeloid leukemia following an allogenic stem cell transplant.

Generations of cancer leads to the risk that must be addressed head-on, but the lessons we can take from our own family members who have had cancer is valuable to pass on.

In an interview with CURE®, lead study investigator of the Keynote 355 trial, Dr. Hope S Rugo, discusses the results of the study that led to the FDA approval of the combination therapy and what further data means for certain patients with metastatic triple-negative breast cancer.

The FDA’s fast track designation for ARX788 to treat patients with advanced or metastatic HER2-positive breast cancer who have received at least one previous anti-HER2-based treatment in the metastatic setting, may open the doors to an accelerated approval.

Life is fleeting, and cancer survivors and caregivers understand that perhaps better than most.

From one leukemia survivor organizing essential blood drives for patients with cancer as COVID-19 delays hit, to a kindergarten teacher handling a recurrence of ovarian cancer by continuing to teach her students through Zoom, here’s what’s happening in the cancer landscape this week.

In an interview with CURE®, the “Felicity” and “Scandal” actor spoke about his experience as a caregiver to his mother, and why women should not just watch and wait for their ovarian cancer to recur.

After being diagnosed with the BARD1 gene and undergoing a preventative double mastectomy, Nina Garcia shares her story to raise awareness and offer hope for other women.

In a recent trial, the addition of chemotherapy to endocrine therapy showed clinical benefit in premenopausal women with lymph node-positive, HR-positive, HER2-negative breast cancer.

A caregiver discusses with her granddaughter the cancer diagnosis and treatment of a loved one.

A roundup of liver cancer news and updates that occurred in 2020 patients with cancer may have missed.

The FDA has not yet reached a decision on an application for the approval of a CAR-T cell therapy product for the treatment of relapsed/refractory large b-cell lymphoma and, according to Bristol Myers Squibb, a new action date for the decision has not been set.

The FDA based its decision on data that demonstrated that the novel therapy in combination with Tecentriq induced a higher overall response to therapy compared to Tecentriq alone in patients with PD-L1-positive non-small cell lung cancer.

Choosing to forego breast reconstruction after breast cancer surgery can cause one to feel like the lone ranger, but that feeling doesn’t last long, especially upon the discovery of an entire flattie tribe.

The FDA granted a priority review to the supplemental new drug application for Lorbrena for the firstline treatment of ALK-positive metastatic non-small cell lung cancer.

A roundup of some skin cancer news and updates that occurred in 2020 that patients may have missed.

Patients with advanced or metastatic kidney cancer treated with the novel drug combination achieved a median progression-free survival of 9.2 months compared to 9.3 months among patients who received Cabometyx with a placebo.

A gynecologic oncology expert from the University of California, Davis reviewed early-stage ovarian cancer and the importance of knowing what options are available before, during and after treatment.

Navigating the scary path of a cancer caregiver possibly becoming the patient with cancer.

A roundup of some kidney cancer news and updates that occurred in 2020 that patients may have missed.

Here's how 3 clinical trials have shaped the overall landscape for patients with HER2 positive breast cancer.

A roundup of some ovarian cancer news and updates that occurred in 2020 that patients may have missed.

Dr. Barry Tong, a genetic counselor in the cancer genetics and prevention program at UCSF, discusses what genetic cancer testing is, the different types of testing, different results, and why going to a genetic counselor beforehand is so important.

Living beyond the statistics and finding a way to celebrate a “cancerversary” with metastatic breast cancer.

The company has withdrawn the small cell lung cancer indication for Opdivo (nivolumab) based on discussions with the FDA, particularly focused on post-market studies that missed their primary endpoints of overall survival.

In participants who reported that the pandemic negatively impacted their decision to enroll in a clinical trial, some of the most common reasons included exposure to the virus and limited access to care.

Waiting is the hardest part when wondering about cancer complications.

In an interview with CURE®, Dr. Wade T. Iams discussed small cell lung cancer, a subtype of lung cancer that starts from neuroendocrine cells in the lung, how different stages are treated and the potential benefits of having a treatment team to communicate with every step of the way.

Here are the top 10 most popular contributor articles from 2020!